FDA Orange Book · active-ingredient family
Terlipressin acetate
Terlipressin acetate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:TERLIVAZ · NDA 022231
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
2
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| TERLIVAZRLD | MALLINCKRODT IRELAND | NDA 022231 | — | Sep 14, 2022 |
Marketing exclusivity (2)
- NCENew chemical entity exclusivity (5 years)
Sep 14, 2027
in 1 yr 3 mo
- ODE-406Orphan-drug exclusivity (7 years)
Sep 14, 2029
in 3 yr 3 mo
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10335452 | Apr 05, 2037 | in 10 yr 11 mo | U-3711 |
Terlipressin acetate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

